Corvus Pharmaceuticals (CRVS) News Today $12.61 -0.47 (-3.59%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.62 +0.01 (+0.04%) As of 05/22/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare ConferenceMay 20 at 4:01 PM | globenewswire.comCorvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too EarlyMay 19, 2026 | seekingalpha.comCorvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call - SlideshowMay 18, 2026 | seekingalpha.comFY2029 Earnings Estimate for CRVS Issued By HC WainwrightMay 18, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Aveanna Healthcare Holdings (AVAH), Phathom Pharmaceuticals (PHAT) and Corvus Pharmaceuticals (CRVS)May 17, 2026 | theglobeandmail.comCorvus Pharmaceuticals, Inc. (CRVS) Shareholder/Analyst Call TranscriptMay 14, 2026 | seekingalpha.comCorvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual MeetingMay 14, 2026 | globenewswire.comReturn To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS)May 10, 2026 | finance.yahoo.comCorvus Pharmaceuticals (NASDAQ:CRVS) Downgraded to "Sell" Rating by Wall Street ZenMay 9, 2026 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Issues Earnings ResultsMay 8, 2026 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above Fifty Day Moving Average After Earnings MissMay 8, 2026 | marketbeat.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comCorvus Pharmaceuticals (CRVS) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3% - Here's WhyApril 29, 2026 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" RatingApril 25, 2026 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's WhyApril 23, 2026 | marketbeat.comCorvus Pharmaceuticals Appoints Andrew C. Chan, M.D.April 23, 2026 | globenewswire.comCorvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID ...April 21, 2026 | finance.yahoo.comCorvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual MeetingApril 21, 2026 | globenewswire.comGoldman Sachs initiates coverage of Corvus Pharmaceuticals (CRVS) with buy recommendationApril 18, 2026 | msn.comCorvus jumps as Goldman Sachs initiates at buy on lead assetApril 17, 2026 | msn.comCRVS stock surges 10%, hits 50-DMA for first time in a month – here’s why Goldman Sachs sees a 166% upsideApril 17, 2026 | msn.comCorvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For SuccessApril 8, 2026 | seekingalpha.comAssessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price GainsMarch 15, 2026 | finance.yahoo.comCorvus Pharmaceuticals rises on atopic dermatitis trial dataMarch 13, 2026 | in.investing.comCorvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ...March 13, 2026 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 earnings call transcriptMarch 13, 2026 | msn.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call TranscriptMarch 12, 2026 | seekingalpha.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026March 5, 2026 | globenewswire.comCorvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 23, 2026 | globenewswire.comIs Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price SurgeFebruary 17, 2026 | finance.yahoo.comCorvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70February 3, 2026 | msn.comMomentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026Three standout stocks for 2026 have already generated massive returns of 56% or more this year, although they may cater to investors with a tolerance for risk.February 2, 2026 | marketbeat.comCorvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 - SlideshowJanuary 27, 2026 | seekingalpha.comCorvus Pharmaceuticals (CRVS) soars 212% on impressive eczema therapy studyJanuary 25, 2026 | msn.comWhy Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 PlansJanuary 24, 2026 | finance.yahoo.comCorvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating ...January 23, 2026 | finance.yahoo.comCorvus Pharmaceuticals Closes Upsized Public Offering, Raising Approximately $201.2 MillionJanuary 23, 2026 | quiverquant.comQCorvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MJanuary 23, 2026 | globenewswire.comCorvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial ResultsJanuary 23, 2026 | msn.comCorvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI GainsJanuary 23, 2026 | marketbeat.comCorvus Pharmaceuticals rises 5%, prices $175M stock offering at $22.15January 22, 2026 | msn.comCRVS stock surges pre-market after Corvus expands equity raise to $175 millionJanuary 22, 2026 | msn.comCorvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockJanuary 21, 2026 | globenewswire.comWhy is CRVS stock rising today?January 21, 2026 | msn.comCorvus Pharmaceuticals slides premarket after unveiling $150M equity raiseJanuary 21, 2026 | msn.comSmart Money Is Betting Big In CRVS OptionsJanuary 21, 2026 | benzinga.comCorvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved UponJanuary 21, 2026 | seekingalpha.com Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.030.44▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼173▲CRVS Articles Average Week Get the Latest News and Ratings for CRVS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Corvus Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Grifols News Apellis Pharmaceuticals News Apogee Therapeutics News CRISPR Therapeutics News Dianthus Therapeutics News Indivior News Legend Biotech News NewAmsterdam Pharma News Kiniksa Pharmaceuticals International News Travere Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
